VEGF Inhibitor Market Players Focus On Combination Therapy For Multiple Benefits


[ad_1]

Vascular Endothelial Growth Factor (VEGF) Inhibitors Market 2021 – Forecast to 2030

The Business Research Company Vascular Endothelial Growth Inhibitors Market 2021 – Opportunities and Strategies – Global Forecast to 2030

LONDON, GREATER LONDON, UK, Nov 30, 2021 /EINPresswire.com/ – Companies in Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Focus On Combination Therapy That Reduces Likelihood Of Resistant Cancer Cell Development . Combination therapy uses different drugs with different effects, so that each drug can be used at its optimal dose, without intolerable side effects. Combination drug therapies are also useful for patients with advanced cancers that are unsuitable for radiation therapy or surgical treatment. For example, in November 2020, the Swiss pharmaceutical company F. Hoffmann-La Roche AG announced that the European Commission (EC) had approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for the treatment of adult patients with hepatocellular carcinoma (HCC) unresectable not having received prior systemic treatment.

TBRC’s Holiday Sale started with discounts on ALL market research reports! Enter your business now.
https://www.thebusinessresearchcompany.com/global-market-reports

The global Vascular Endothelial Growth Factor Inhibitors market size reached a value of nearly $ 30.31 billion in 2020, after increasing at a compound annual growth rate (CAGR) of 7.8% since 2015. The VEGF inhibitor market is expected to grow from $ 30.31 billion in 2020 to $ 46.64 billion in 2025 at a rate of 9.0%. The market is then expected to grow at a CAGR of 6.3% from 2025 and reach $ 63.38 billion in 2030.

North America was the largest region in the global vascular endothelial growth factor (VEGF) inhibitor market, accounting for 49.0% of the total in 2020. It was followed by Asia Pacific and then other regions. Looking ahead, the fastest growing regions in the Vascular Endothelial Growth Factor Inhibitors market will be Eastern Europe and South America where the growth will be 14.6% and respectively 13.1%. These will be followed by Africa and the Middle East, where markets are expected to grow at CAGRs of 12.2% and 12.0% respectively.

Learn more about the Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market report:
https://www.thebusinessresearchcompany.com/report/vascular-endothelial-growth-factor-inhibitor-market

The increasing prevalence of cancer is a key driver for the growth of the Vascular Endothelial Growth Factor Inhibitors market. Cancer is considered the second leading cause of death worldwide, with around 1 in 6 deaths from cancer. According to the American Cancer Society, there were a total of 1.8 million new cancer cases and 0.60 million deaths in the United States in 2020, or approximately 4,950 new cases and over 1,600 deaths each. day. About 70% of cancer deaths occur in low- and middle-income countries. The International Agency for Research on Cancer estimates that by 2040, the number of new cancer cases per year will increase to 29.5 million and the number of cancer-related deaths will rise to 16.4 million worldwide. Hence, the increasing prevalence of cancer is expected to drive the growth of the VEGF inhibitors market.

The major players covered by the global VEGF inhibitor industry are F. Hoffmann-La Roche AG, Bayer AG, Regeneron Pharmaceuticals, Inc., Astrazeneca Plc., Novartis AG.

Global TBRC VEGF Inhibitor Market report is segmented by Drug Type into Avastin, Tecentriq, Cometriq, Eylea, Others, Oral, Intravenous, Oncology Application, Ophthalmology, Others.

Vascular Endothelial Growth Factor (VEGF) Inhibitors Market 2021 – By Drug Type (Eylea, Avastin, Tagrisso, Tecentriq), By Administration (Intravenous, Intravitreal, Oral), By Application (Oncology, Ophthalmology) And By Region, Opportunities and Strategies – Global Forecast To 2030 is part of a series of new reports from The Business Research Company that provides Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Overview, Size and Forecast Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Growth For Overall Market, Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Segments, Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Analysis , Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Growth, Endothelial Growth Factor Inhibitors Market Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Geographies, Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Trends, Vascular Endothelial Growth Factor (VEGF) Inhi Bitor Market Overview, Drivers Vascular Endothelial Growth Factor (VEGF) Inhibitors Market, restraints, revenue, profiles and market share of key competitors.

Request for Sample of Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3949&type=smp

Here is a list of similar reports from the trade research company:

Global Protein Inhibitors Market Report 2021 – By Product (Protein Kinase Inhibitors, Monoclonal Antibody), By Application (Oncology, Inflammatory Diseases), By Distribution Channel (Hospital Pharmacies, Independent Pharmacies, Online Pharmacies), Growth and evolution of COVID-19
https://www.thebusinessresearchcompany.com/report/protein-inhibitors-global-market-report-2020-30-covid-19-growth-and-change

Global Vascular Grafts Market Report 2021 – By Product (Hemodialysis Access Graft, Endovascular Stent Graft, Peripheral Vascular Graft, Coronary Artery Bypass Graft), By Raw Material (Polyester Grafts, ePTFE, Polyurethane Grafts , biosynthetic transplants), by application (coronary grafts) Arterial disease, aneurysm, vascular occlusion, renal failure), by end user (hospitals, outpatient surgery centers), growth and course of COVID-19
https://www.thebusinessresearchcompany.com/report/vascular-grafts-global-market-report-2020-30-covid-19-growth-and-change

Global Oncology Biosimilars Market Report 2021 – By Drug Type (Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony Stimulating Factor (G-CSF)), By Cancer Type (Breast Cancer, Colorectal Cancer, blood cancer, neutropenia cancer, non-small cell lung cancer), by type of distribution (hospital pharmacy, retail pharmacy, online pharmacy), growth and course of COVID-19
https://www.thebusinessresearchcompany.com/report/oncology-biosimilars-market-global-report

Want to learn more about The Business Research Company?

The Business Research Company is a market research and intelligence company that excels in business, market and consumer research. It has more than 200 research professionals in offices in India, the UK and the US, as well as a network of trained researchers around the world. It has consultants who specialize in a wide range of industries including manufacturing, healthcare, financial services and technology.

Learn more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

Or get a quick overview of our services here: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

The commercial research company
Email: info@tbrc.info
Follow us on LinkedIn: https://bit.ly/3b7850r
Follow us on Twitter: https://bit.ly/3b1rmjS
Check out our Blog: http://blog.tbrc.info/

Olivier Guirdham
The commercial research company
+44 20 7193 0708
info@tbrc.info
Visit us on social networks:
Facebook
Twitter
LinkedIn


[ad_2]

Comments are closed.